Related Experiment Video
Updated: Nov 22, 2025
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Blocking the Spinal Fbxo3/CARM1/K+ Channel Epigenetic Silencing Pathway as a Strategy for Neuropathic Pain Relief
Ming-Chun Hsieh1, Yu-Cheng Ho2, Cheng-Yuan Lai1
1Department of Medicine, Mackay Medical College, No.46, Sec. 3, Zhongzheng Rd, Sanzhi Dist, New Taipei, 25245, Taiwan.
Abstract:
Many epigenetic regulators are involved in pain-associated spinal plasticity. Coactivator-associated arginine methyltransferase 1 (CARM1), an epigenetic regulator of histone arginine methylation, is a highly interesting target in neuroplasticity. However, its potential contribution to spinal plasticity-associated neuropathic pain development remains poorly explored. Here, we report that nerve injury decreased the expression of spinal CARM1 and induced allodynia. Moreover, decreasing spinal CARM1 expression by Fbxo3-mediated CARM1 ubiquitination promoted H3R17me2 decrement at the K+ channel promoter, thereby causing K+ channel epigenetic silencing and the development of neuropathic pain. Remarkably, in naïve rats, decreasing spinal CARM1 using CARM1 siRNA or a CARM1 inhibitor resulted in similar epigenetic signaling and allodynia. Furthermore, intrathecal administration of BC-1215 (a novel Fbxo3 inhibitor) prevented CARM1 ubiquitination to block K+ channel gene silencing and ameliorate allodynia after nerve injury. Collectively, the results reveal that this newly identified spinal Fbxo3-CARM1-K+ channel gene functional axis promotes neuropathic pain. These findings provide essential insights that will aid in the development of more efficient and specific therapies against neuropathic pain.
Insights
Nerve injury reduces spinal CARM1, promoting neuropathic pain via epigenetic silencing of K+ channels. Inhibiting Fbxo3-CARM1 interaction ameliorates pain, revealing a new therapeutic target for neuropathic pain.
Area of Science:
- Neuroscience
- Epigenetics
- Pain Research
Background:
- Epigenetic regulators influence spinal plasticity and neuropathic pain.
- Coactivator-associated arginine methyltransferase 1 (CARM1) is a key epigenetic regulator.
- The role of CARM1 in neuropathic pain development is largely unknown.
Purpose of the Study:
- To investigate the role of CARM1 in spinal plasticity and neuropathic pain.
- To identify the molecular mechanisms underlying CARM1's involvement in pain.
- To explore potential therapeutic targets for neuropathic pain.
Main Methods:
- Investigated CARM1 expression in rats following nerve injury.
- Utilized CARM1 siRNA and inhibitors to modulate CARM1 activity.
- Examined histone modifications (H3R17me2) at K+ channel gene promoters.
- Administered Fbxo3 inhibitor (BC-1215) to assess its therapeutic potential.
Main Results:
- Nerve injury decreased spinal CARM1 expression and induced allodynia.
- Fbxo3-mediated CARM1 ubiquitination reduced H3R17me2, leading to K+ channel silencing and pain.
- CARM1 inhibition in naïve rats mimicked injury-induced epigenetic changes and allodynia.
- BC-1215 treatment blocked CARM1 ubiquitination, prevented K+ channel silencing, and reduced allodynia.
Conclusions:
- A novel Fbxo3-CARM1-K+ channel gene axis promotes neuropathic pain.
- CARM1 is a critical mediator of spinal plasticity in neuropathic pain.
- Targeting the Fbxo3-CARM1 pathway offers a promising strategy for neuropathic pain treatment.
